The eagerly-awaited results of the TOPCAT trial were recently made available by the New England Journal of Medicine. In it, 3445 patients with HFPEF were randomized to spironolactone or placebo. The investigators found no significant difference in the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for heart failure. There did appear to be a significantly lower risk of the hospitalization component among the treatment group. As such, we are still left with a dearth of specific agents to treat HFPEF.
Primecuts – This Week In The Journals http://t.co/ZCWg1F1Gvs
Clinical Pathological Conference 4.25.2014 – The Protocol http://t.co/Ea0JzcB11o
Primecuts – This Week In The Journals http://t.co/QdmoKaE4mX
Should Physicians Ask Patients about Guns? http://t.co/HAXjA2Erp3
Is the anti-flu effectiveness of oseltamivir in question? http://t.co/Dn3SAwS9AN